Association between early immunophenotypic changes and therapeutic response of belimumab in patients with systemic lupus erythematosus. (January 2023)

• Record Type: Journal Article
• Authors: Hirano, Aiko; Fujioka, Kazuki; Kida, Takashi; Omura, Satoshi; Sofue, Hideaki; Sakashita, Aki; Sagawa, Tomoya; Isoda, Yu; Kasahara, Akiko; Sagawa, Risa; Fujii, Wataru; Seno, Takahiro; Wada, Makoto; Kohno, Masataka; Kawahito, Yutaka
• Is Part Of: Lupus. Volume 32:Number 1(2023)
• Page Start: 63
• Page End: 73
• Publication Date: 2023-01
• Subjects: Belimumab -- immunophenotype -- systemic lupus erythematosus -- SLE; Systemic lupus erythematosus -- Periodicals; 616.772005
• DOI: 10.1177/09612033221137249
• Languages: English
• ISSNs: 0961-2033

Abstract

Belimumab is a therapeutic medication that inhibits the B-cell-activating factor (BAFF) used for systemic lupus erythematosus (SLE); however, the response sometimes varies among individuals, even when patients are stratified based on general clinical characteristics. Therefore, we focused on immunological phenotypic changes with belimumab, investigated their association with subsequent clinical courses, and sought to identify relevant immunological indicators to stratify patients who would benefit from belimumab. We assessed changes in B and T cell phenotypes, as well as BAFF-related factors, such as levels of BAFF and a proliferation-inducing ligand, and expression of three BAFF receptors: BAFF receptor (BAFF-R), B-cell maturation antigen (BCMA), transmembrane activator and cyclophilin ligand interactor (TACI), in 19 patients with SLE who were treated with belimumab before and 3 months after treatment. First, to visualize patterns in complex and diverse data, we summarized B cell changes such as subsets and BAFF receptor expressions into two axes, the first and second principal components (PC1 and PC2), and characterized broad phenotypic changes by cluster analysis. Next, we evaluated whether the B cell changes represented by PC1 and PC2 were associated with other concurrent phenotypic changes, baseline factors, and treatment response at 6 months. We found that lower PC2, indicating increased BAFF-R expression and decreased percentage of naïve B cells, was associated with a subsequent therapeutic response at 6 months (odds ratio 5.3, 95% confidence interval 1.2–24, p = .031). Furthermore, higher percentages of effector memory CD3+CD4+ T cells at baseline were associated with lower PC2 and therapeutic response. Further analysis revealed that increased PC1, as reflected by increased BCMA and TACI expression and an increase in the percentage of class-switched memory B cells, was associated with both T and B cell activation. Although belimumab is a B-cell targeted therapy, it can also influence T-cell phenotypes. Thus, early B cell changes could be used to predict treatment response, and their changes could be predicted from baseline T cell phenotypes, indicating the importance of B and T cell interactions.